NDAC in '01
This article was originally published in The Tan Sheet
Executive Summary
Tentative Dec. 7-8 meeting cancelled; next scheduled meeting date is May 10-11, 2001. NDAC evaluated five subjects in 2000. In July, the committee considered issues related to the relaunch of the Today Sponge by Allendale Pharmaceuticals and the Rx-to-OTC switch applications for cholesterol-lowering statin drugs Mevacor (Merck) and Pravachol (Bristol-Myers Squibb). In October, NDAC met to discuss phenylpropanolamine use in cough/cold and weight loss products, as well as AstraZeneca/P&G's switch application for the proton pump inhibitor Prilosec